Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945597 | 0.89 | F2RL3 (0.59) | F2RL3MAPTFYNLMNATP53 | |
| SCHEMBL1944295 | 0.88 | F2RL3 (0.61) | F2RL3MAPTRXFP1FYNTP53 | |
| SCHEMBL15603219 | 0.88 | F2RL3 (0.58) | F2RL3MAPTFYNLMNATP53 | |
| SCHEMBL1945297 | 0.88 | F2RL3 (0.56) | F2RL3MAPTFYNTP53EGFR | |
| SCHEMBL1945508 | 0.87 | F2RL3 (0.50) | F2RL3MAPTFYNLMNATP53 | |
| SCHEMBL1945651 | 0.87 | F2RL3 (0.53) | F2RL3MAPTFYNLMNATP53 | |
| SCHEMBL1947352 | 0.87 | F2RL3 (0.52) | F2RL3MAPTFYNTP53PTGDR | |
| SCHEMBL1944596 | 0.87 | FYN (0.51) | F2RL3MAPTFYNTP53PTGDR | |
| SCHEMBL2257279 | 0.87 | FYN (0.56) | F2RL3MAPTFYNLMNATP53 | |
| SCHEMBL1944019 | 0.86 | F2RL3 (0.53) | F2RL3MAPTFYNLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | F2RL3 1121/4885MAPT 4021/4885RXFP1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.